BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuasa T, Yamamoto S, Urakami S, Fukui I, Yonese J. Denosumab: a new option in the treatment of bone metastases from urological cancers. Onco Targets Ther 2012;5:221-9. [PMID: 23055747 DOI: 10.2147/OTT.S30578] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Samir Abdelhafiz A, Wassef M, Alorabi M. Pleural empyema due to Salmonella in a patient with bronchogenic carcinoma: the first case report from a cancer hospital in Egypt. Access Microbiol 2020;2:acmi000151. [PMID: 33195981 DOI: 10.1099/acmi.0.000151] [Reference Citation Analysis]
2 Vijayaraghavalu S, Gao Y, Rahman MT, Rozic R, Sharifi N, Midura RJ, Labhasetwar V. Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis. Biomaterials 2020;227:119558. [PMID: 31654872 DOI: 10.1016/j.biomaterials.2019.119558] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
3 Yamasaki M, Yuasa T, Uehara S, Fujii Y, Yamamoto S, Masuda H, Fukui I, Yonese J. Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab. Int J Clin Oncol 2016;21:1191-5. [PMID: 27402103 DOI: 10.1007/s10147-016-1019-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Balachandran K, Popat S. Endocrine manifestations of malignancy. Medicine 2013;41:570-2. [DOI: 10.1016/j.mpmed.2013.07.005] [Reference Citation Analysis]
5 Masuda H, Kaga K, Inahara M, Araki K, Kojima S, Naya Y, Takano M. Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer. Urol Case Rep 2017;13:63-5. [PMID: 28462158 DOI: 10.1016/j.eucr.2016.11.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
6 Dahiya N, Khadka A, Sharma AK, Gupta AK, Singh N, Brashier DB. Denosumab: A bone antiresorptive drug. Med J Armed Forces India. 2015;71:71-75. [PMID: 25609868 DOI: 10.1016/j.mjafi.2014.02.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
7 Gravina GL, Tortoreto M, Mancini A, Addis A, Di Cesare E, Lenzi A, Landesman Y, McCauley D, Kauffman M, Shacham S, Zaffaroni N, Festuccia C. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol 2014;7:46. [PMID: 25284315 DOI: 10.1186/1756-8722-7-46] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]